Designing a broad-spectrum integrative approach for cancer prevention and treatment

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages S276-S304

  Block, Keith I ^a   Gyllenhaal, Charlotte ^a   Lowe, Leroy ^b,ec   Amedei, Amedeo ^c   Ruhul Amin, A R M ^d   Amin, Amr ^e   Aquilano, Katia ^f   Arbiser, Jack ^d,ao,eb   Arreola, Alexandra ^g   Arzumanyan, Alla ^h   Salman Ashraf, S ^e   Azmi, Asfar S ⁱ   Benencia, Fabian ^j   Bhakta, Dipita ^k   Bilsland, Alan ^l   Bishayee, Anupam ^m   Blain, Stacy W ⁿ   Block, Penny B ^a   Boosani, Chandra S ^o   Carey, Thomas E ^p   Carnero, Amancio ^q   Carotenuto, Marianeve ^r,s   Casey, Stephanie C ^t   Chakrabarti, Mrinmay ^u   Chaturvedi, Rupesh ^v   Chen, Georgia Zhuo ^d   Chen, Helen ^w   Chen, Sophie ^x   Chen, Yi Charlie ^y   Choi, Beom K ^z   Ciriolo, Maria Rosa ^f   Coley, Helen M ^aa   Collins, Andrew R ^ab   Connell, Marisa ^w   Crawford, Sarah ^ac   Curran, Colleen S ^ad   Dabrosin, Charlotta ^ae   Damia, Giovanna ^af   Dasgupta, Santanu ^ag   DeBerardinis, Ralph J ^ai   Decker, William K ^aj   Dhawan, Punita ^ak   Diehl, Anna Mae E ^al   Dong, Jin Tang ^d   Dou, Q Ping ⁱ   Drewa, Janice E ^am   Elkord, Eyad ^an   El Rayes, Bassel ^ao   Feitelson, Mark A ^h   Felsheru, Dean W ^t   Ferguson, Lynnette R ^ap   Fimognari, Carmela ^aq   Firestone, Gary L ^ar   Frezza, Christian ^as   Fujii, Hiromasa ^at   Fuster, Mark M ^au   Generali, Daniele ^av,aw   Georgakilas, Alexandros G ^ax   Gieseler, Frank ^ay   Gilbertson, Michael ^b   Green, Michelle F ^az   Grue, Brendan ^ba   Guhal, Gunjan ^k   Halicka, Dorota ^bb   Helferich, William G ^bc   Heneberg, Petr ^bd   Hentosh, Patricia ^be   Hirschey, Matthew D ^al,az   Hofseth, Lorne J ^bf   Holcombe, Randall F ^bg   Honoki, Kanya ^at   Hsu, Hsue Yin ^bh   Huang, Gloria S ^bi   Jensen, Lasse D ^ae,bj   Jiang, Wen G ^bk   Jones, Lee W ^bl   Karpowicz, Phillip A ^bm   Keith, W Nicol ^l   Kerkar, Sid P ^bn   Khan, Gazala N ^bo   Khatami, Mahin ^bp   Ko, Young H ^bq   Kucuk, Omer ^d   Kulathinal, Rob J ^h   Kumar, Nagi B ^br   Kwon, Byoung S ^z,ah   Leb, Anne ^bt   Leab, Michael A ^bu   Lee, Ho Young ^bv   Lichtor, Terry ^bw   Lin, Liang Tzung ^bx   Locasale, Jason W ^by   Lokeshwar, Bal L ^bz   Longo, Valter D ^ca   Lyssiotis, Costas A ^cb   MacKenzie, Karen L ^cc   Malhotra, Meenakshi ^cd   Marino, Maria ^ce   Martinez Chantar, Maria L ^cf   Matheu, Ander ^cg   Maxwellx, Christopher ^w   McDonnell, Eoin ^az   Meeker, Alan K ^bt   Mehrmohamadi, Mahya ^by   Mehta, Kapil ^ch   Michelotti, Gregory A ^al   Mohammad, Ramzi M ⁱ   Mohammed, Sulma I ^ci   Morre, D James ^cj   Muqbil, Irfana ⁱ   Muralidharcq, Vinayak ^ck,cl   Murphy, Michael P ^cm   Nagaraju, Ganji Purnachandra ^ao   Nahta, Rita ^d   Niccolai, Elena ^cn   Nowsheen, Somaira ^co   Panis, Carolina ^cp   Pantano, Francesco ^cq   Parslow, Virginia R ^ap   Pawelec, Graham ^cr   Pedersen, Peter L ^bt   Poore, Brad ^bt   Poudyal, Deepak ^bf   Prakash, Satya ^cd   Prince, Mark ^cb   Raffaghello, Lizzia ^cs   Rathmell, Jeffrey C ^az   Rathmell, W Kimryn ^g   Ray, Swapan K ^u   Reichrath, Jörg ^ct   Rezazadeh, Sarallah ^cu   Ribatti, Domenico ^cv,ed   Ricciardiello, Luigi ^aq   Robeydf, R Brooks ^cw,cx   Rodierdh, Francis ^cy,cz   Rupasinghe, H P Vasantha ^ba   Russo, Gian Luigi ^da   Ryan, Elizabeth P ^db   Samadi, Abbas K ^dc   Sanchez Garcia, Isidro ^dd   Sanders, Andrew J ^bk   Santini, Daniele ^cq   Sarkar, Malancha ^de   Sasada, Tetsuro ^df   Saxena, Neeraj K ^dg   Shackelford, Rodney E ^dh   Shantha Kumara, H M C ^bs   Sharma, Dipali ^bt   Shin, Dong M ^d   Sidransky, David ^bt   Siegelin, Markus David ^di   Signori, Emanuela ^dj   Singh, Neetu ^dk   Sivanand, Sharanya ^dl   Sliva, Daniel ^dm   Smythe, Carl ^dn   Spagnuolo, Carmela ^da   Stafforini, Diana M ^do   Stagg, John ^cy   Subbarayan, Pochi R ^dp   Sundin, Tabetha ^dq   Talib, Wamidh H ^dr   Thompson, Sarah K ^ds   Tran, Phuoc T ^bt   Ungefroren, Hendrik ^ay   Vander Heiden, Matthew G ^cl   Venkateswaran, Vasundara ^dt   Vinay, Dass S ^ah   Vlachostergios, Panagiotis J ^du   Wang, Zongwei ^dv   Wellen, Kathryn E ^dl   Whelan, Richard L ^bs   Yang, Eddy S ^dw   Yang, Huanjie ^dx   Yang, Xujuan ^bc   Yaswen, Paul ^dy   Yedjou, Clement ^dz   Yin, Xin ^au   Zhu, Jiyue ^ea   Zollo, Massimo ^r,s   more..

^a Block Center for Integrative Cancer Treatment   (United States)

^b Getting to Know Cancer   (Canada)

^c UNIVERSITY OF FLORENCE   (Italy)

^d EMORY UNIVERSITY   (United States)

^e UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h Temple University   (United States)

ⁱ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j OHIO UNIVERSITY   (United States)

^k SASTRA UNIVERSITY   (India)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m Larkin Health Science Institute   (United States)

ⁿ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^o CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF MICHIGAN   (United States)

^q CSIC   (Spain)

^r Centro di Ingegneria Genetica e Biotecnologia Avanzate CEINGE   (Italy)

^s UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^t STANFORD UNIVERSITY   (United States)

^u UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^v JAWAHARLAL NEHRU UNIVERSITY   (India)

^w UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^x Ovarian and Prostate Cancer Research Trust Laboratory   (United Kingdom)

^y Alderson Broaddus College   (United States)

^z National Cancer Center   (South Korea)

^aa UNIVERSITY OF SURREY   (United Kingdom)

^ab UNIVERSITY OF OSLO   (Norway)

^ac SOUTHERN CONNECTICUT STATE UNIVERSITY   (United States)

^ad UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^ae LINKÖPING UNIVERSITY   (Sweden)

^af MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^ag UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^ah TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^ai UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^aj BAYLOR COLLEGE OF MEDICINE   (United States)

^ak VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^al DUKE UNIVERSITY MEDICAL CENTER   (United States)

^am ROWETT RESEARCH INSTITUTE   (United Kingdom)

^an UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^ao EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ap UNIVERSITY OF AUCKLAND   (New Zealand)

^aq UNIVERSITY OF BOLOGNA   (Italy)

^ar UNIVERSITY OF CALIFORNIA   (United States)

^as UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^at NARA MEDICAL UNIVERSITY   (Japan)

^au UNIVERSITY OF CALIFORNIA   (United States)

^av UNIVERSITY OF TRIESTE   (Italy)

^aw CREMONA HOSPITAL   (Italy)

^ax NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^ay UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^az DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ba DALHOUSIE UNIVERSITY   (Canada)

^bb NEW YORK MEDICAL COLLEGE   (United States)

^bc UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^bd CHARLES UNIVERSITY   (Czech Republic)

^be OLD DOMINION UNIVERSITY   (United States)

^bf UNIVERSITY OF SOUTH CAROLINA   (United States)

^bg MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^bh TZU CHI UNIVERSITY   (Taiwan)

^bi ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^bj KAROLINSKA INSTITUTE   (Sweden)

^bk CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^bl MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bm UNIVERSITY OF WINDSOR   (Canada)

^bn MAYO CLINIC   (United States)

^bo HENRY FORD HOSPITAL   (United States)

^bp NATIONAL CANCER INSTITUTE   (United States)

^bq UNIVERSITY OF MARYLAND   (United States)

^br H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^bs ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^bt JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bu RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^bv Seoul National University   (South Korea)

^bw RUSH UNIVERSITY MEDICAL CENTER   (United States)

^bx TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^by University of Southern California ^*  (United States)

^bz MEDICAL COLLEGE OF GEORGIA   (United States)

^ca UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^cb UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^cc CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^cd MCGILL UNIVERSITY   (Canada)

^ce ROMA TRE UNIVERSITY   (Italy)

^cf INSTITUTO DE SALUD CARLOS III   (Spain)

^cg BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^ch UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ci PURDUE UNIVERSITY   (United States)

^cj PURDUE UNIVERSITY   (United States)

^ck HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^cl MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^cm UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^cn UNIVERSITY OF FLORENCE   (Italy)

^co MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^cp UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ   (Brazil)

^cq UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^cr UNIVERSITY OF TÜBINGEN   (Germany)

^cs G GASLINI INSTITUTE   (Italy)

^ct SAARLAND UNIVERSITY   (Germany)

^cu UNIVERSITY OF ROCHESTER   (United States)

^cv UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^cw VA MEDICAL CENTER   (United States)

^cx DARTMOUTH MEDICAL SCHOOL   (United States)

^cy CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^cz UNIVERSITÉ DE MONTRÉAL   (Canada)

^da CNR   (Italy)

^db Veterinary Dentistry and Oral Surgery   (United States)

^dc Sanus Biosciences   (United States)

^dd UNIVERSITY OF SALAMANCA   (Spain)

^de University of Miami   (United States)

^df KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^dg UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^dh LOUISIANA STATE UNIVERSITY   (United States)

^di Department of Medicine   (United States)

^dj INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^dk KING GEORGE'S MEDICAL UNIVERSITY   (India)

^dl UNIVERSITY OF PENNSYLVANIA   (United States)

^dm Purdue Research Park   (United States)

^dn UNIVERSITY OF SHEFFIELD   (United Kingdom)

^do UNIVERSITY OF UTAH   (United States)

^dp UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^dq SENTARA HEALTHCARE   (United States)

^dr APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

^ds ROYAL ADELAIDE HOSPITAL   (Australia)

^dt SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^du LUTHERAN MEDICAL CENTER   (United States)

^dv MASSACHUSETTS GENERAL HOSPITAL   (United States)

^dw UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^dx HARBIN INSTITUTE OF TECHNOLOGY   (China)

^dy LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^dz Jackson State University   (United States)

^ea WASHINGTON STATE UNIVERSITY   (United States)

^eb ATLANTA VA MEDICAL CENTER   (United States)

^ec LANCASTER UNIVERSITY   (United Kingdom)

^ed NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

more..

Author keywords

Cancer hallmarks; Integrative medicine; Multi targeted; Phytochemicals; Targeted therapy

Indexed keywords

ANTHOCYANIN; BELINOSTAT; BERBERINE; CURCUMIN; DEGUELIN; DINACICLIB; ENTEROLACTONE; EPIGALLOCATECHIN GALLATE; GAMMA LINOLENIC ACID; GENISTEIN; GOSSYPOL; ICOSAPENTAENOIC ACID; IMETELSTAT; KAEMPFEROL; LUTEOLIN; LYCOPENE; MELATONIN; NARINGENIN; NATURAL PRODUCT; PALBOCICLIB; PERILLYL ALCOHOL; RESVERATROL; ROMIDEPSIN; SELINEXOR; SILIBININ; TRIPTOLIDE; UNINDEXED DRUG; VORINOSTAT; WITHAFERIN A; ZERUMBONE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER PREVENTION; CANCER THERAPY; CELL IMMORTALIZATION; COLORECTAL CANCER; DIETARY INTAKE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENOMIC INSTABILITY; HUMAN; INFLAMMATION; INTEGRATIVE MEDICINE; INTERDISCIPLINARY COMMUNICATION; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PATENT; PHENOTYPE; PHYTOCHEMISTRY; RECURRENCE RISK; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SOYBEAN; TUMOR ESCAPE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; DRUG RESISTANCE; GENETIC HETEROGENEITY; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84952918579     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.09.007     Document Type: Review

References (261)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, EserS, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from http://globocan.iarc.fr [cited 17.07.14].
2. Palumbo MO, Kavan P, Miller Jr WH, Panasci L, Assouline S, Johnson N, et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol 2013;4:57.
3. Block KI. Life Over Cancer. New York: Bantam; 2009. p. 594.
4. Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy. Acta Clin Belg 2011;66(1):2-9.
5. Abdel-Hafiz HA, Horwitz KB. Role of epigenetic modifications in luminal breast cancer. Epigenomics 2015;17:1-16.
6. Vogelstein B, Papadoupoulos N, Velculescu VE, Shou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
7. NiraulaS, Seruga B, Ocana A, ShaoT, Goldstein R, Tannock IF, et al. The price we pay for progress: a meta-analysis of harms of newly approved cancer drugs. J Clin Oncol 2012;30(24):3012-9.
8. Motzer RJ, HutsonTE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90.
9. Hollebecque A, Massard C, De Baere T, Auger N, Lacroix L, Koubi-Pick V, et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial - interim results. J Clin Oncol 2013, suppl: Abstr 2512. Presented at 2013 ASCO Annual Meeting, Chicago IL.
10. Weiss GJ, Liang WS, Demeure MJ, KieferJA, Hostettter G, Izatt T, et al. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLOS ONE 2013;8(10):e76438.
11. Anonymous. ESMO2014: Final Survival Analysis from the CLEOPATRA Study in Patients with HER-2 Positive Metastatic Breast Cancer [Internet]. European Society for Medical Oncology; 2014. Available from: http://www. esmo.org/Conferences/ESMO-2014-Congress/News-Articles/Final-Overall- Survival-Analysis-from-the-CLEOPATRA-Study-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer (Copyright 2014, cited 03.10.14).
12. Kefford R, Ribas A, Hamid O, Robert C, Daud A, WolchokJD, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.J Clin Oncol 2014;32(5s) (suppl; abstr 3005).
13. Ribas A, Tumeh PC. The future of cancer therapy: selecting patients who respond to PD-1/L1 blockade. Clin Cancer Res 2014;20(19):4982-4.
14. WolchokJD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33.
15. Rees L, Weil A. Integrated medicine. Br Med J 2001;322(7279): 119-20.
16. Block KI, Gyllenhaal C. Chapter 6: Nutritional interventions in cancer. In: Abrams D, Weil A, editors. Integrative Oncology. New York: Oxford University Press; 2014. p. 120-59.
17. Courtice MN, Lin S, Wang X. An updated review on asbestos and related diseases in China. Int J Occup Environ Health 2012;18(3):247-53.
18. Iyoke CA, Ugwu GO, Ezugwu EC, Ezugwu FO, Lawani OL, Onyebuchi AK. Challenges associated with the management of gynecological cancers in a tertiary hospital in South East Nigeria. Int J Womens Health 2014;6:123-30.
19. Ciociola AA, Cohen LB, Kulkarni P. FDA-related matters committee ofthe American college of gastroenterology. How drugs are developed and approved by the FDA: current process and future directions. Am J Gastroenterol 2014;109(5):620-3.
20. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection ofthe unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121(22):4439-42.
21. Zaric GS, Sehgal C. The Challenge of Access to Oncology Drugs in Canada. Harvard Business Review; 2009. Available at: http://hbr.org/product/thechallenge- of-access-to-oncology-drugs-in-canad/an/909E20-PDF-ENG.
22. Zahreddine H, Borden KLB. Mechanisms and insights into drug resistance in cancer. Front Pharmacol 2013;4:28.
23. RingashJ, Au HJ, Siu LL, Shapiro JD, JonkerDJ, ZalcbergJR, et al. Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer 2014;120(2):181-9.
24. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 2014;63(4):407-18.
25. WeberJS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013;31(34):4311-8.
26. Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by The International Initiative for accelerated improvement of glioblastoma care. Oncotarget 2013;4:502-30.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
29. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
30. VerhoeffJJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444.
31. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U. S. A 2005;102(27):9714-9.
32. Quaranta V, Tyson DR. What lies beneath: looking beyond tumor genetics shows the complexity of signaling networks underlying drug sensitivity. Sci Signal 2013;6(294):pe32.
33. Ferarrelli LK. Focus issue: networking cancer treatment strategies. Sci Signal 2013;6(294):eg5.
34. Zhai B, SunXY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013;5(7):345-52.
35. Bishayee A. The role of inflammation and liver cancer. Adv Exp Med Biol 2014;816:401-35.
36. Muqbil I, Bao GW, El-Kharraj R, Shah M, Mohammad RM, Sarkar FH, et al. Systems and network pharmacology approaches to cancer stem cells research and therapy. J Stem Cell ResTher 2012;Suppl 7(5), pii: 10413.
37. Kelley DS, Rasooly R, Jacob RA, Kader AA, Mackey BE. Consumption of Bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and women. J Nutr 2006;136(4):981-6.
38. Peairs AT, Rankin JW. Inflammatory response to a high-fat, low-carbohydrate weight loss diet: effect of antioxidants. Obesity (Silver Spring) 2008;6(7):1573-8.
39. Jolad SD, Lantz RC, Solyom AM, Chen GJ, Bates RB, Timmermann BN. Fresh organically grown ginger (Zingiber officinale): composition and effects on LPS-induced PGE2 production. Phytochemistry 2004;65(13):1937-54.
40. Block KI, Gyllenhaal C, Tripathy D, Freels S, Mead MN, Block PB, et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. Breast J 2009;15(4):357-66.
41. Block KI, Gyllenhaal C. Breast cancer. In: Kohlstadt I, editor. Advancing Medicine with Food and Nutrients. 2nd ed. Boca Raton, FL: CRC Press, Taylor & Francis Group LLC; 2012. p. 727-42.
42. Hanahan D. Rethinking the war on cancer. Lancet 2014;383(9916): 558-63.
43. McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer 2014;50(16):2763-70.
44. Marrone M, Stewart A, Dotson WD. Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews. Genet Med 2014, December. Online publication ahead of print.
45. Schmeiser HH, NortierJL, Singh R, da Costa GG, SennesaelJ, Cassuto-Viguier E, et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 2014;135(2):502-7.
46. Ermolaeva MA, Schumacher B. Systemic DNA damage responses: organismal adaptations to genome instability. Trends Genet 2014;30(3):95-102.
47. Ding X, Zhang B, Pei Q, Pan J, Huang S, Yang Y, et al. Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1. BMC Cancer 2014;14(1):271.
48. Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U. Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol 2012;74(3):424-36.
49. Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis 2015;74(6):1078-86.
50. Bastos LF, Coelho MM. Drug repositioning: playing dirty to kill pain. CNS Drugs 2014;28(1):45-61.
51. Hu QN, Deng Z, Tu W, YangX, Meng ZB, Deng ZX, Liu J. NP: interactive visual network pharmacology of diseases, targets, and drugs. CPT Pharmacomet Syst Pharmacol 2014;3:e105.
52. Dudhatra GB, Mody SK, Awale MM, Patel HB, Modi CM, Kumar A, et al. A comprehensive review on pharmacotherapeutics of herbal bioenhancers. Sci World J 2012;2012:637953.
53. Zanella F, Link W, Carnero A. Understanding FOXO new views on old transcription factors. Curr Cancer Drug Targets 2010;10(2):135-46.
54. Feitelson MA, Lian Z, Liu J, Tufan NL, Pan J. Parallel epigenetic and genetic changes in hepatitis B virus associated hepatocellular carcinoma. Cancer Lett 2006;239(1):10-20.
55. Vinay DS, Kwon BS. 41BB(CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep 2014;47(3):122-9.
56. de Miranda Torrinhas RS, Santana R, Garcia T, Cury-Boaventura MF, Sales MM, Curi R, Waitzberg DL. Parenteral fish oil as a pharmacological agent to modulate post-operative immune response: a randomized, double-blind, and controlled clinical trial in patients with gastrointestinal cancer. Clin Nutr 2013;32(4):503-10.
57. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother 2013;62(3):405-10.
58. Russo M, Spagnulo C, Tedesco I, Russo GL. Phytochemicals in cancer prevention and therapy: truth or dare? Toxins 2010;2:517-51.
59. Aravindan S, Natarajan M, Herman TS, Awasthi V, Aravindan N. Molecular basis of'hypoxic' breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling. Radiat Oncol 2013;8:46.
60. Huq F, Yu JQ, Beale P, Chan C, Arzuman L, Nessa MU, et al. Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer. Anticancer Res 2014;34(1):541-5.
61. Chu ES, Sze SC, Cheung HP, Liu Q, Ng TB, Tong Y. An in vitro and in vivo investigation of the antimetastatic effects of a Chinese medicinal decoction, Erxian decoction, on human ovarian cancer models. Integr Cancer Ther 2013;12(4):336-46.
62. Liu X, Li Y, Zeng F, Huang Y, Zhou J, Wang Y, et al. Chan-Yu-Bao-Yuan-Tang, the water extract of a Chinese medicine prescription, induces s-phase arrest and mitochondria-mediated apoptosis in human lung adenocarcinoma cells. Integr Cancer Ther 2012;11(4):337-53.
63. Wu P, DugouaJJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res 2009;28:112.
64. Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 2013;71(6):1521-30.
65. Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLOS ONE 2013;8(11):e81968.
66. Du M, YangX, HartmanJA, Cooke PS, Doerge DR, Ju YH, et al. Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis 2012;33(4):895-901.
67. Hasima N, Aggarwal BB. Cancer-linked targets modulated by curcumin. Int J. Biochem Mol Biol 2012;3(4):328-51.
68. McCarty MF, Block KI. Multifocal angiostatic therapy: an update. Integr Cancer Ther 2005;4(4):301-14.
69. McCarty MF, Block KI. Toward a core nutraceutical program for cancer management. Integr Cancer Ther 2006;5(2):150-71.
70. Subbarayan PR, Sarkar M, Nathanson L, Doshi N, Lokeshwar BL, Ardalan B. In vitro global gene expression analyses support the ethnopharmacological use of Achyranthes aspera. Evid Based Complement Alternat Med 2013;2013:471739.
71. Deocaris CC, Widodo N, Wadhwa R, Kaul SC. Merger of ayurveda and tissue culture-based functional genomics: inspirations from systems biology. J Transl Med 2008;6:14.
72. Dwivedi V, Anandan EM, Mony RS, Muraleedharan TS, Valiathan MS, Mutsuddi M, et al. In vivo effects of traditional ayurvedic formulations in Drosophila melanogaster model relate with therapeutic applications. PLoS ONE 2012;7(5):e37113.
73. Lee SC, ChanJY, Pervaiz S. Spontaneous and 5-fluorouracil-induced centrosome amplification lowers the threshold to resveratrol-evoked apoptosis in colon cancer cells. Cancer Lett 2010;288:36-41.
74. Rusin M, Zajkowicz A, Butkiewicz D. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulationof BRCA1. Mech Aging Dev 2009;130:528-37.
75. Ferguson L, Schlothauer R. The potential role of nutritional genomics tools in validating high health foods for cancer control: broccoli as example. Mol Nutr Food Res 2012;56(1):126-46.
76. Donkena KV, Yuan H, Young CY. Vitamin Bs, one carbon metabolism and prostate cancer. Mini Rev Med Chem 2010;10:1385-92.
77. Hopkins MH, Owen J, AhearnT, Fedirko V, Flanders WD, Jones DP, et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res (Phila) 2011;4:1645-54.
78. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of antiinflammatory activity. J Bone Miner Res 2007;22(Suppl 2):V74-80.
79. Kristal A, Arnold K, Neuhouser M, Goodman P, Platz E, Albanes D, et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2010;172:566-77.
80. Sharp L, Carsin AE, Cantwell MM, Anderson LA, Murray LJ, Group FS. Intakes of dietary folate and other B vitamins are associated with risks of esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis. J Nutr 2013;143:1966-73.
81. Trejo-Solís C, Pedraza-Chaverrí J, Torres-Ramos M, Jiménez-Farfán D, Cruz Salgado A, et al. Multiple molecular and cellular mechanisms of action of lycopene in cancer inhibition. Evid Based Complement Alternat Med 2013;2013:705121.
82. Zhang X-H, Ma J, Smith-Warner S, Lee J, Giovannucci E. Vitamin B6 and colorectal cancer: current evidence and future directions. World J Gastroenterol 2013;19(7):1005-10.
83. Vicente-Duenas C, Perez-Caro M, Abollo-Jimenez F, Cobaleda C, Sanchez-Garcia I. Stem-cell driven cancer: "hands-off" regulation of cancer development. Cell Cycle 2009;8:1314-8.
84. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
85. Ji RC. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett 2014;346:6-16.
86. Luo D, Wang Z, Wu J, Jiang C, WuJ. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int 2014;2014:409272.
87. Ohnishi K, Semi K, Yamada Y. Epigenetic regulation leading to induced pluripotency drives cancer development in vivo. Biochem Biophys Res Commun 2014;455(1-2):10-5.
88. Easwaran H, Tsai HC, BaylinSB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014;54: 716-27.
89. Costantini S, ColonnaG, CastelloG. A holistic approach to study the effects of natural antioxidants on inflammation and liver cancer. Cancer Treat Res 2014;159:311-23.
90. Pan MH, Chiou YS, Wang YJ, Ho CT, Lin JK. Multistage carcinogenesis process as molecular targets in cancer chemoprevention by epicatechin-3-gallate. Food Funct 2011;2:101-10.
91. ThakurVS, Gupta K, Gupta S. The chemopreventive and chemotherapeutic potentials of tea polyphenols. Curr Pharm Biotechnol 2012;13:191-9.
92. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
93. Godbout R, DryjaTP, Squire J, Gallie BL, Phillips RA. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 1983;304:451-3.
94. Sage J, Straight AF. RB's original CIN? Genes Dev 2010;241:329-1333.
95. Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol 2013;792:109-31.
96. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014;25:304-17.
97. Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011;117:677-87.
98. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett 2009;19:706-9.
99. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279:51163-71.
100. NandakumarV, Vaid M, KatiyarSK. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 2011;32:537-44.
101. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-70.
102. Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U. S. A 2012;109:7765-9.
103. Du Toit A. Cell death: balance through a bivalent regulator. Nat Rev Mol Cell Biol 2013;14:546-7.
104. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist. Update 2003;6:169-72.
105. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010;46:308-16.
106. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004;36:984-8.
107. Artandi SE, DePinho RA. A critical role fortelomeres in suppressing and facilitating carcinogenesis. CurrOpin Genet Dev 2000;10:39-46.
108. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U. S. A 1996;93:13742-7.
109. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 1999;19:2109-17.
110. Schwarze SR, Fu VX, DesotelleJA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005;7:816-23.
111. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
112. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-79.
113. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, JaskelioffM, et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012;148:651-63.
114. BensingerSJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol 2012;23:352-61.
115. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324(5930):1029-33.
116. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N EnglJ Med 2009;360(8):813-5.
117. Lee C, Longo VD. Fasting vs. dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene 2011;30(30):3305-16.
118. KunduJK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008;659:15-30.
119. GrivennikovSI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
120. Mantovani A. Cancer: inflaming metastasis. Nature 2009;457:36-7.
121. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010;33:335-51.
122. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
123. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21.
124. Ohnishi S, Ma N, Thanan R, Pinlaor S, Hammam O, Murata M, et al. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev 2013;2013:387014.
125. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85.
126. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-91.
127. Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem Biophys 2009;55:55-79.
128. FolkmanJ. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
129. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004;14:139-45.
130. SemenzaGL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003;54:17-28.
131. KambaT, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290(2): H560-76.
132. Yang Y, Zhang Y, Cao Z, Ji H, YangX, Iwamoto H, et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U. S. A 2013;110(29):12018-23.
133. KambaT, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. BrJ Cancer 2007;96:1788-95.
134. Chatterjee S, Bhattacharjee B. Use of natural molecules as antiangiogenic inhibitors for vascular endothelial growth factor receptor. Bioinformation 2012;8:1249-54.
135. TalmadgeJE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010;70:5649-69.
136. Sporn MB. The war on cancer: a review. Ann NY Acad Sci 1997;833:137-46.
137. Guyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
138. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
139. Kenney PA, Lee GY, Bissell MJ. Targeting the tumor microenvironment. Front Biosci 2007;12:3468-74.
140. ShiaoSL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011;25:2559-72.
141. Casey SC, Li Y, Fan AC, Felsher DW. Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer 2014;2:24.
142. WeberJ. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007;12: 864-72.
143. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12.
144. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999;22:431-40.
145. Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B, Das BK. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010;17(1):21.
146. Xu J, LiuXS, Zhou SF, Wei MQ. Combination of immunotherapy with anerobic bacteria for immunogene therapy of solid tumors. Gene Ther Mol Biol 2009;13:36-52.
147. Daviglus ML, Liu K, Pirzada A, Yan LL, Garside DB, Wang R, et al. Relationship of fruit and vegetable consumption in middle-aged men to Medicare expenditures in older age: the Chicago Western Electric Study. J Am Diet Assoc 2005;105:1735-44.
148. Academic Consortium for Integrative Medicine. Definition of Integrative Medicine; 2015. Available from: http://www.imconsortium.org/about/about-us.cfm (copyright 2015, cited 4/10/15).
149. Block KI, Block PB, Gyllenhaal C. Integrative therapies in cancer: modulating abroad spectrum of targets for cancer management. Integr Cancer Ther 2015;14(2):113-8.
150. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, DC: AICR; 2007.
151. RockCL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA: Cancer J Clin 2012;62(4):243-74.
152. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. J Am Med Assoc 2007;298(7):754-64.
153. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006;98(24):1767-76.
154. MontonenJ, Boeing H, Fritsche A, Schleicher E, Joost HG, Schulze MB, et al. Consumption of red meat and whole-grain bread in relation to biomarkers of obesity, inflammation, glucose metabolism and oxidative stress. EurJ Nutr 2013;52(1):337-45.
155. Neuhouser ML, Schwarz Y, Wang C, Breymeyer K, Coronado G, Wang CY, Noar K, Song X, Lampe JW. A low-glycemic load diet reduces serum C-reactive protein and modestly increases adiponectin in overweight and obese adults. J Nutr 2012;142(2):369-74.
156. Davis NJ, Crandall JP, Gajavelli S, BermanJW, Tomuta N, Wylie-Rosett J, et al. Differential effects of low-carbohydrate and low-fat diets on inflammation and endothelial function in diabetes. J Diabetes Complicat 2011;25(6):371-6.
157. Urpi-Sarda M, Casas R, Chiva-BlanchG, Romero-Mamani ES, Valderas-Martínez P, Arranz S, Andres-Lacueva C, Llorach R, Medina-Remón A, Lamuela-Raventos RM, Estruch R. Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomarkers related to atherosclerosis. Pharmacol Res 2012;65(6):577-83.
158. Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, et al. Effect of low-fat diets on plasma levels of NF-KB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) 2011;4(10):1590-8.
159. Pendyala S, NeffLM, Suárez-Farinas M, Holt PR. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr 2011;93(2):234-42.
160. Karlsen A, Retterstøl L, Laake P, Paur I, Bøhn SK, Sandvik L, et al. Anthocyanins inhibit nuclear factor-kappaB activation in monocytes and reduce plasma concentrations of proinflammatory mediators in healthy adults. J Nutr 2007;137(8):1951-4.
161. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun 2011;25(8): 1725-34.
162. Eremin O, Walker MB, Simpson E, Heys SD, Ah-See AK, Hutcheon AW, et al. Immunomodulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomised controlled trial. Breast 2009;18(1):17-25.
163. Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, et al. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun 2010;24(8):1231-40.
164. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006;24(22):3535-41.
165. Fong DY, Ho JW, Hui BP, Lee AM, Macfarlane DJ, Leung SS, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. Br Med J 2012;344:e70.
166. Kruijsen-Jaarsma M, Révész D, Bierings MB, Buffart LM, Takken T. Effects of exercise on immune function in patients with cancer: a systematic review. Exerc Immunol Rev 2013;19:120-43.
167. Friedenreich CM, Woolcott CG, McTiernan A, Ballard-Barbash R, Brant RF, Stanczyk FZ, et al. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol 2010;28(9):1458-66.
168. Jiang 1 J, Eliaz I, Sliva D. Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells. Integr Cancer Ther 2013;12(2):145-52.
169. Bishayee A, Thoppil RJ, Waghray A, KruseJA, Novotny NA, Darvesh AS. Dietary phytochemicals in the chemoprevention and treatment of hepatocellular carcinoma: in vivo evidence, molecular targets, and clinical relevance. Curr Cancer Drug Targets 2012;12(9):1191-232.
170. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med 2013;11(2):110-20.
171. Darvesh AS, Bishayee A. Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer. Nutr Cancer 2013;65(3):329-44.
172. Setchell KD, Brown NM, ZhaoX, Lindley SL, Heubi JE, King EC, et al. Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. Am J Clin Nutr 2011 Nov;94(5):1284-94.
173. Marks C. Mouse models of human cancer consortium (MMHCC) from NCI. Dis Model Mech 2009;2(3-4):111.
174. Gordon I, Paoloni M, Mazcko C, KhannaC. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6(10):e1000161.
175. Goshima H, Saji S, Furuta T, Taneumura H, Takao H, Kida H, Takahashi H. Experimental study on preventive effects of lung metatastases using LAK cells induced from various lymphocytes-special references to enhancement of lung metastasis after laparotomy stress. J Jpn SurgSoc 1989;90: 1245-50.
176. Allendorf JDF, Bessler M, Kayton ML, Oesterling SD, Treat MR, Nowygrod R, Whelan RL. Increased tumor establishment and growth after laparotomy vs. laparoscopy in a murine model. Arch Surg 1995;130:649-53.
177. Eggermont AM, Steller EP, Marquet RL, JeekelJ, Sugarbaker PH. Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cells. Cancer Detect Prev 1988;12:421-9.
178. Peeters CF, de Waal RM, Wobbes T, Westphal JR, Ruers TJ. Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer 2006;119:1249-53.
179. Lange PH, Hekmat K, Bosl G, et al. Accelerated growth of testicular cancer after cytoreductive surgery. Cancer 1980;45:1498-506.
180. Crawford SE, Flores-Stadler EM, Huang L, TanXD, Ranalli M, Mu Y, Gonzalez-Crussi F. Rapid growth of cutaneous metastases after surgical resection of thrombospondin-secreting small blue round cell tumor of childhood. Hum Pathol 1998;29(10):1039-44.
181. Shantha Kumara HM, Cabot JC, YanX, HerathSA, Luchtefeld M, Kalady MF, et al. Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection. Surg Endosc 2011;25(7):2153-8.
182. Shantha Kumara HM, Tohme ST, Herath SA, YanX, Senagore AJ, Nasar A, et al. Plasma soluble vascular adhesion molecule-1 levels are persistently elevated during the first month after colorectal cancer resection. Surg Endosc 2012;26(6):1759-64.
183. Kumara HM, Shantha, Feingold D, Kalady M, Dujovny N, Senagore A, Hyman N, et al. Colorectal resection is associated with persistent proangiogenic plasma protein changes: postoperative plasma stimulates in vitro endothelial cell growth, migration, and invasion. Ann Surg 2009;249(6):973-7.
184. Shantha Kumara HM, KirchoffD, Naffouje S, Grieco M, Herath SA, Dujovny N, et al. Plasma from the second and third weeks after open colorectal resection for cancer stimulates in vitro endothelial cell growth, migration, and invasion. Surg Endosc 2012;26(3):790-5.
185. Kim IY, Yan X, Tohme S, Ahmed A, Cordon-Cardo C, Shantha Kumara HM, et al. CpG ODN, Toll Like Receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model. J Surg Res 2012;174(2):284-90.
186. Carter JJ, Feingold DL, Oh A, Kirman I, Wildbrett P, Stapleton G, et al. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surg Innov 2006;13(1):41-7.
187. Wildbrett P1, Oh A, Carter JJ, Schuster H, Bessler M, Jaboci CA, Whelan RL. Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of this effect with perioperative immunomodulation. Surg Endosc 2002;16(8):1162-70.
188. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol Epigallocatechin-3-gallate. Cancer Res 2006;66(5):2500-5.
189. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008;269(2):352.
190. YanX, GardnerTR, Grieco M, Herath SA, JangJH, KirchoffD, et al. Perioperative Polyphenon E- and siliphos-inhibited colorectal tumor growth and metastases without impairment of gastric or abdominal wound healing in mouse models. Surg Endosc Surg Endosc 2012;26(7):1856-64.
191. LiX, Yang G, LiX, Zhang Y, Yang J, Chang J, SunX, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese. PLOS ONE 2013;8(4):e60338.
192. GagnierJJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 2006;144(5):364-7.
193. ShergisJL, Zhang AL, Zhou W, Xue CC. Quality and risk of bias in Panax ginseng randomized controlled trials: a review. Am J Chin Med 2013;41(2):231-52.
194. Gescher A, Steward WP, Brown K. Resveratrol in the management of human cancer: how strong is the clinical evidence? Ann N Y Acad Sci 2013;1290:12-20.
195. Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, Markowitz JS. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers a dose escalation study. Drug Metab Dispos 2013;419(9):1679-85.
196. Morris ME, Dave RA. Pharmacokinetics and pharmacodynamics of phenethyl isothiocyanate: implications in breast cancer prevention. AAPS J 2014;16(4):705-13.
197. Russo GL, Russo M, Spagnuolo C, Tedesco I, Bilotto S, Iannitti R, Palumbo R. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat Res 2014;159:185-205.
198. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern Med Rev 2000 Jun;5(3):196-208.
199. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2001;(8S Suppl):2073S-85S.
200. Pereira AG, Fajardo AR, Nocchi S, Nakamura CV, Rubira AF, Muniz EC. Starch-based microspheres for sustained-release of curcumin: preparation and cytotoxic effect on tumor cells. Carbohydr Polym 2013;98(1):711-20.
201. Ranjan AP, Mukerjee A, Helson L, Gupta R, VishwanathaJK. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis. Anticancer Res 2013;33(9):3603-9.
202. Shehzad A, Ul-Islam M, Wahid F, Lee YS. Multifunctional polymeric nanocurcumin for cancer therapy. J Nanosci Nanotechnol 2014;14(1):803-14.
203. Chen Y, Kuehl GE, BiglerJ, Rimorin CF, Schwarz Y, Shen DD, et al. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenet Genomics 2007;17(8):571-9.
204. BohnT. Dietary factors affecting polyphenol bioavailability. Nutr Rev 2014;72(July (7)):429-52.
205. Hanhineva K, Aura AM, Rogachev I, Matero S, Skov T, Aharoni A, et al. In vitro microbiotic fermentation causes an extensive metabolite turnover of rye bran phytochemicals. PLoS ONE 2012;7(6):e39322.
206. van Breemen RB, Fong HH, Farnsworth NR. Ensuring the safety of botanical dietary supplements. Am J Clin Nutr 2008;87(2):509S-13S.
207. Sovak M, Seligson AL, Konas M, Hajduch M, Dolezal M, Machala M, Nagourney R. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 2002;94(17):1275-81.
208. Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, et al. Future development of global regulations of Chinese herbal products. J Ethnopharmacol 2012;140:568-86.
209. Huang EC, Zhao Y, Chen G, Baek SJ, McEntee MF, Minkin S, et al. Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells. BMC Complement Altern Med 2014;14:68.
210. CapodiceJL, Gorroochurn P, Cammack AS, Eric G, McKiernanJM, Benson MC, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 2009;7(2):43-51.
211. Wong AY, Chan AW. Myriad and its implications for patent protection of isolated natural products in the United States. Chin Med 2014;9:17.
212. Health Canada. Pathway for Licensing Natural Health Products making Modern Health Claims [Internet]. Ottawa, ON: Health Canada; 2014. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/legislation/docs/modern-eng.php (No copyright. Updated 27.12.12; cited 13.04.14).
213. World Health Organization. National Policy on Traditional Medicine and Regulation of Herbal Medicines. Report of a WHO Global Survey. Geneva, Switzerland: World Health Organization; 2005.
214. Wang Y, FanX, Qu H, GaoX, Cheng Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine. CurrTop Med Chem 2012;12(12):1356-62.
215. Medicines and Healthcare Products Regulatory Agency. Permitted Indications Under the Directive on Traditional Herbal Medicinal Products [Internet]. London: The Agency. C; 2014. Available from: http://www.mhra. gov.uk/home/groups/es-herbal/documents/websiteresources/con009363. pdf (cited 13.04.14).
216. Sachan V, Kohli Y, Gautam R. Regulatory issues for herbal products - a review [Internet], Greater Noida, UP., India; 2010. Available from: http://www.scribd.com/doc/26680241/REGULATORY-ISSUES-FOR-HERBALPRODUCTS- A-REVIEW (cited 08.07.14).
217. GaoJJ, Song PP, Qi FH, Kokudo N, Qu XJ, Tang W. Evidence-based research on traditional Japanese medicine, Kampo in treatment of gastrointestinal cancer in Japan. Drug DiscovTher 2012;6(1):1-8.
218. Rugo H, Stivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, et al. Phase I trial and antitumor effects of BZL101 for patients with metastatic breast cancer. Breast Cancer Res Treat 2007;105(1):17-28.
219. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, KimmickGG, Cohen I, et al. A phase IB dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat 2010;120(1):111-8.
220. Saif MW, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, Bussom S, et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2014;73(2):373-80.
221. MeltzerSM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol 2009;200(3), 233.e1-7.
222. Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol 2010;77(1):69-78.
223. Krattiger A, Mahoney RT, Nelsen L, ThomsonJA, Bennet AB, Satyanarayana K, et al., editors. Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices. Oxford, UK/US: Center for the Management of Intellectual Property, and Davis/Public Intellectual Property Resources for Agriculture; 2007.
224. He SM, Yang AK, Li XT, Du YM, Zhou SF. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 2010;6(10):1195-213.
225. Fuentes E, Palomo I. Relationship between platelet PPARs, cAMP Levels, and P-selectin expression: antiplatelet activity of natural products. Evid Based Complement Alternat Med 2013;2013:861786.
226. Mousa SA. Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol 2010;663:229-40.
227. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006;62(3):225-33.
228. Ge J, Tan BX, Chen Y, Yang L, PengXC, Li HZ, et al. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berl) 2011;89(6):595-602.
229. Lu Y, Sun J, Petrova K, YangX, GreenhawJ, Salminen WF, et al. Metabolomics evaluation of the effects of green tea extract on acetaminophen-induced hepatotoxicity in mice. Food Chem Toxicol 2013;62:707-21.
230. Amin AR, KucukO, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009;27(16):2712-25.
231. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62(7):919-30.
232. Rao S, DinkarC, VaishnavLK, Rao P, Rai MP, Fayad R, et al. The Indian spice turmeric delays and mitigates radiation-induced oral mucositis in patients undergoing treatment for head and neck cancer: an investigational study. Integr Cancer Ther 2013;13(3):201-10.
233. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 2013;105(16):1230-8.
234. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 2013;3(1):120144.
235. Panis C, Victorino VJ, Herrera AC, Freitas LF, De Rossi T, Campos FC, et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res. Treat 2012;133(3):881-8.
236. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008;123(6):1227-39.
237. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, et al. Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 2012;133(1):89-97.
238. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007;33(5):407-18.
239. Ullah MF, Ahmad A, Khan HY, Zubair H, Sarkar FH, Hadi SM. The prooxidant action of dietary antioxidants leading to cellular DNA breakage and anticancer effects: implications for chemotherapeutic action against cancer. Cell Biochem Biophys 2013;67(2):431-8.
240. Azmi AS, Sarkar FH, Hadi SM. Prooxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property. F1000Res 2013;2:135.
241. Manello F, Tonti GA, Pagliarini S, Benedetti S, Canestrari F, Zhu W, et al. The 8-epimer of prostaglandin f(2 alpha), a marker of lipid peroxidation and oxidative stress, is decreased in the nipple aspirate fluid of women with breast cancer. Int J Cancer 2007;120(9):1971-6.
242. Backos DS, Franklin CC, Reignan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol 2012;83:1005-12.
243. Mencalha A, Victorino VJ, Cecchini R, Panis C. Mapping oxidative damage in breast cancer: understanding the basic to reach the clinics. Anticancer Res 2014;34(3):1127-40.
244. Paul SM, Mytelka DS, Dunwiddie CT, PersingerCC, Munos BH, Lindborg SR, et al. How to improve R and D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9(3):203-14.
245. Malaney P, Nicosia SV, Davé V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett 2014;344(1):1-12.
246. U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals and Safety Notifications, [about 2 screens], [Internet]. Washington: The Administration; 2015. Available from: http://www.fda. gov/drugs/informationondrugs/approveddrugs/ucm279174.htm (updated 1/10/15, cited 4/10/15).
247. Crawford S. Antiinflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence. Ther Adv Med Oncol 2014;6(2):52068.
248. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8 g extension study. Am J Hematol 2012;87(5):455-60.
249. Shivappa N, Hébert JR, Rietzschel ER, De Buyzere ML, Langlois M, Debruyne E, et al. Associations between dietary inflammatory index and inflammatory markers in the Asklepios study. Br J Nutr 2015;113(4):665-71.
250. Tabung FK, SteckSE, Ma Y, Liese AD, Zhang J, et al. The association between dietary inflammatory index and risk of colorectal cancer among postmenopausal women: results from the Women's Health Initiative. Cancer Causes Control 2014;26(3):399-408.
251. Kondo A, TakedaT, Li B, Tsuiji K, Kitamura M, Wong TF, Yaegashi N. Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis. Int J Clin Oncol 2013;18(3):380-8.
252. Xiong F, Jiang M, Huang Z, Chen M, Chen K, Zhou J, et al. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells. Integr Cancer Ther 2014;13(2):152-60.
253. Wang P, Chen Z, Meng ZQ, Luo JM, Lin JH, Zhou ZH, et al. Ski acts as therapeutic target of qingyihuaji formula in the treatment of SW1990 pancreatic cancer. Integr Cancer Ther 2010;9(1):50-8.
254. Stoner GD. Foodstuffs for preventing cancer; the preclinical and clinical development of berries. Cancer Prev Res (Phila) 2009;(293):187-94.
255. Ishikawa H, Saeki T, Otani T, Suzuki T, Shimozuma K, Nishino H, et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr 2006;136(3 Suppl):816S-20S.
256. ChenT, Yan F, QianJ, Guo M, Zhang H, TangX, et al. Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus. Cancer Prev Res (Phila) 2012;5(1): 41-50.
257. Xu JD, MaoQ, Shen H, Zhu LY, Li SL, Yan R. Ultra-high performance liquid chromatography coupled with photo-diode array and quadrupole/time-offlight mass spectrometry based chemical profiling approach to evaluate the influence of preparation methods on the holistic quality of Qiong-Yu-Gao, a traditional complex herbal medicine. J Chromatogr A 2013;1304:154-68.
258. Kinghorn AD, Carcache de Blanco EJ, Chai HB, OrjalaJ, Farnsworth NR, Soejarto DD, et al. Discovery of anticancer agents of diverse natural origin. Pure Appl Chem 2009;81(6):1051-63.
259. Farnsworth NR, Mahady GB. Research highlights from the UIC/NIH Center for Botanical Dietary Supplements Research for Women's Health: Black cohosh from the field to the clinic. Pharm Biol 2009;47(8): 755-60.
260. WeaverCM, Barnes S, WyssJM, Kim H, Morré DM, Morré DJ, et al. Research highlights from the Purdue-UAB Botanicals Research Center for Age Related Diseases. Pharm Biol 2009;47(8):768-73.
261. Cramer H, Cohen L, Dobos G, Witt CM. Integrative oncology: best of both worlds-theoretical, practical, and research issues. Evid Based Complement Alternat Med 2013;2013:383142.